Cessation of Mr. Ashok Kumar (DIN: 07647876) from the directorship of the company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech's board, at its meeting on 15 January 2026, approved the standalone unaudited financial results for the quarter and nine months ended 31 December 2025. For Q3FY26, revenue from operations stood at Rs. 5,00,000 with a profit of Rs. 1,05,206 (EPS Rs. 0.03), compared to Rs. 22,00,950 revenue and Rs. 15,53,756 profit in the year-ago quarter. For the 9-month period, revenue fell sharply to Rs. 23,00,000 from Rs. 58,04,300 last year, with profit dropping to Rs. 3,84,786 from Rs. 43,05,297. Additionally, Mr. Ashok Kumar (DIN: 07647876) ceased to be a director and member of all committees of the company with immediate effect, under Section 167 of the Companies Act, 2013, due to non-completion of KYC requirements. The limited review was conducted by Andros & Co., Chartered Accountants, with no qualifications.
The sharp year-on-year decline in both revenue (~60%) and profit (~91%) for the 9-month period is a worrying sign for shareholders. The director's exit under Section 167 for KYC non-compliance is a governance red flag, though this is a relatively routine statutory vacation rather than a misconduct-related removal.